$15.6m for TriReme's third funding round:
This article was originally published in Clinica
Executive Summary
Pleasanton, California-based TriReme Medical has raised $15.6m in new capital to fund the development and ongoing clinical trials of its single-balloon bifurcation stent system. The series C financing came from lead investor Three Arch Partners and Adams Street Partners. TriReme said its device has a lower profile than standard bifurcation stent systems. In addition, the delivery system is the only one of its kind that allows the doctor to actively determine the orientation of the stent prior to deployment, thereby ensuring precise positioning.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.